Detalles de la búsqueda
1.
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
Haematologica
; 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38031804
2.
Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol
; 17(4): 411-422, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33115291
3.
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
Breast Cancer Res Treat
; 157(1): 145-56, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27107569
4.
Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States.
Value Health
; 18(6): 876-83, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26409616
5.
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer.
Value Health
; 18(4): 541-6, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26091608
6.
Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden.
Breast Cancer Res Treat
; 144(3): 673-81, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24596047
7.
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
BMC Cancer
; 14: 307, 2014 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-24885258
8.
Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
BMC Pediatr
; 14: 261, 2014 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-25308481
9.
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma.
J Med Econ
; 27(1): 738-745, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38686393
10.
Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy.
BMC Pediatr
; 13: 97, 2013 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-23782528
11.
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
J Med Econ
; 26(1): 1134-1144, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674384
12.
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Clin Lymphoma Myeloma Leuk
; 23(11): e393-e404, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37704514
13.
Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.
BMC Infect Dis
; 12: 95, 2012 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22520624
14.
Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.
BMC Pediatr
; 12: 81, 2012 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-22721493
15.
Frequency, duration and predictors of bronchiolitis episodes of care among infants ≥32 weeks gestation in a large integrated healthcare system: a retrospective cohort study.
BMC Health Serv Res
; 12: 144, 2012 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-22682080
16.
Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.
Clin Lymphoma Myeloma Leuk
; 22(2): 121-128, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34674981
17.
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Lancet Haematol
; 9(4): e289-e300, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358443
18.
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
J Manag Care Spec Pharm
; 27(5): 615-624, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33586513
19.
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
J Comp Eff Res
; 9(14): 1003-1015, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33028076
20.
Maintenance rituximab in Veterans with follicular lymphoma.
Cancer Med
; 9(20): 7537-7547, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32860335